Sugi Predict

Sugi Predict / Compounds / SCHEMBL759010

SCHEMBL759010

SCHEMBL759010

NC(=O)CC[C@H](NCC=CO)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.42
▸ ALOX15 P16050 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ MMP2 P08253 2/20 0.38
▸ MMP9 P14780 2/20 0.38
▸ CA2 P00918 5/20 0.38
▸ CA1 P00915 4/20 0.38
▸ GGT1 P19440 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ FOLH1 Q04609 3/20 0.35
▸ RIMKLA Q8IXN7 1/20 0.35
▸ NAALAD2 Q9Y3Q0 1/20 0.35
▸ DPP4 P27487 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP9 Q86TI2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27390881 1.00 KMT2A (0.42) KMT2AALOX15BLMPMP22MMP2
SCHEMBL10355087 0.86 FOLH1 (0.50) FOLH1RIMKLANAALAD2
SCHEMBL757319 0.82 ECE1 (0.38) KMT2ACA2CA1GGT1
Phosphoric Acid SCHEMBL27542271 0.81 KMT2A (0.39) KMT2AALOX15BLMPMP22MMP2
SCHEMBL3083190 0.81 KMT2A (0.39) KMT2AALOX15BLMPMP22MMP2
SCHEMBL21226 0.81 KMT2A (0.43) KMT2AALOX15BLMPMP22MMP2
SCHEMBL627104 0.81 KMT2A (0.43) KMT2AALOX15BLMPMP22MMP2
SCHEMBL21225 0.81 KMT2A (0.43) KMT2AALOX15BLMPMP22MMP2
SCHEMBL149082 0.76 KMT2A (0.48) KMT2AALOX15BLMPMP22MMP2
SCHEMBL8768913 0.76 KMT2A (0.48) KMT2AALOX15BLMPMP22MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230302146-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac SE (DE) 2023-09-28 — — US claimed
US-20230190578-A1 REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS CureVac SE (DE) 2023-06-22 — — US claimed
US-20210378977-A1 Dry Powder Formulations for Messenger RNA TRANSLATE BIO INC (US) 2021-12-09 — — US claimed
EP-3826608-A1 DRY POWER FORMULATIONS FOR MESSENGER RNA Translate Bio, Inc. (US) 2021-06-02 — — EP claimed
US-10952970-B2 Use of vitelline protein B as a microencapsulating additive THE TEXAS A&M UNIVERSITY SYSTEM (US) 2021-03-23 — — US claimed
US-20200338215-A1 DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS CUREVAC AG (DE) 2020-10-29 — — US claimed
US-20200316189-A1 VACCINATION IN NEWBORNS AND INFANTS CUREVAC AG (DE) 2020-10-08 — — US claimed
US-10751424-B2 Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids CUREVAC AG (DE) 2020-08-25 — — US claimed
US-20200179526-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac SE (DE) 2020-06-11 — — US claimed
WO-2020023533-A1 DRY POWER FORMULATIONS FOR MESSENGER RNA TRANSLATE BIO, INC. (US) 2020-01-30 — — WO claimed
EP-2164631-A1 MODIFYING DRUG RELEASE IN SUSPENSIONS OF IONIC RESIN SYSTEMS Neos Therapeutics, LP (US) 2010-03-24 — — EP claimed
WO-2010012940-A2 MICROPARTICULATE ORAL DRUG FORM USEFUL FOR THE MODIFIED RELEASE OF NANOPARTICLES FLAMEL TECHNOLOGIES (FR) 2010-02-04 — — WO claimed
US-20100021549-A1 Microparticle oral form useful for the modified release of nanoparticles FLAMEL TECHNOLOGIES, S.A. (FR) 2010-01-28 — — US claimed
WO-2009037313-A1 AMPHIPHILIC COPOLYMERS AND COMPOSITIONS CONTAINING SUCH POLYMERS NIRVANA'S TREE HOUSE B.V. (NL) 2009-03-26 — — WO claimed
US-20090011027-A1 Modifying Drug Release in Suspensions of Ionic Resin Systems NEOS THERAPEUTICS, LP (US) 2009-01-08 — — US claimed
WO-2008151071-A1 MODIFYING DRUG RELEASE IN SUSPENSIONS OF IONIC RESIN SYSTEMS NEOS THERAPEUTICS, LP (US) 2008-12-11 — — WO claimed
US-20060193877-A1 Compositions and methods of making sustained release liquid formulations PFAB, LP (US) 2006-08-31 — — US claimed
US-20050260258-A1 Use of vitelline protein B as a microencapsulating additive THE TEXAS A&M UNIVERSITY SYSTEM (US) 2005-11-24 — — US claimed
US-6565872-B2 A composite polymer system comprising a stimuli-responsive polymer selected from R-acrylamide, R1-acryalate, R2-acrylic acid, polyethylene glycol(R,R1,R2=H or alkyl) at least one second polymer such as, polysaccharide, cellulose, polyester Wu, Xiao Yu (CA) 2003-05-20 — — US claimed
US-4116949-A WATER-SOLUBLE, PHYSIOLOGICALLY ACTIVE, SYNTHETIC COPOLYPEPTIDES THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1978-09-26 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210378977-A1 Dry Powder Formulations for Messenger RNA RNMT, NSUN3, NSUN2 KMT2A 1763/4885ALOX15 955/4885BLM 2630/4885
US-20100021549-A1 Microparticle oral form useful for the modified release of nanoparticles MC1R, PTMS, MRPL37 KMT2A 4857/4885ALOX15 1826/4885BLM 4391/4885
US-20200179526-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO HNRNPH1, HNRNPH3, SNRPE KMT2A 3349/4885ALOX15 2734/4885BLM 967/4885
US-20230302146-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO HNRNPH1, HNRNPH3, SNRPE KMT2A 3349/4885ALOX15 2734/4885BLM 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.